One of the significant benefits of Ponatinib is its ability to overcome resistance to other TKIs. This makes it a crucial option for patients who have developed resistance to first-line and second-line treatments. Clinical trials have shown that Ponatinib can induce remission in patients with advanced stages of CML and Ph+ ALL.
